Research programme - anti-fibrotic therapeutics - Evotec SE/Variant Bio
Latest Information Update: 22 Apr 2024
At a glance
- Originator Evotec SE; Variant Bio
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis